靶向CDK7抑制超增强子驱动的致癌转录在未分化甲状腺癌中的作用
本研究探讨未分化甲状腺癌(ATC)中超增强子(SE)驱动的致癌转录成瘾机制,并通过高通量化学筛选发现CDK7共价抑制剂THZ1。ATC细胞而非甲状腺乳头状癌细胞对CDK7抑制异常敏感,整合分析揭示SE介导的致癌转录扩增是ATC细胞对THZ1敏感的基础,并发现PPP1R15A、SMG9和KLF2等新癌基因。PPP1R15A表达与CDK7表达相关,两者高表达均与ATC患者不良预后相关,抑制CDK7或PPP1R15A可使ATC细胞对常规化疗敏感。
要点
- CDK7抑制剂THZ1在ATC细胞中显示强效抗增殖作用,而甲状腺乳头状癌细胞不敏感。
- SE驱动的致癌转录扩增是ATC对CDK7抑制敏感的基础。
- PPP1R15A和CDK7高表达与ATC患者不良预后相关,抑制二者可增敏化疗。
核心结论
- ATC存在转录成瘾,CDK7和PPP1R15A可作为潜在生物标志物和治疗靶点。
研究设计与样本
- 研究采用高通量化学筛选、细胞活力与集落形成分析、细胞周期分析、动物实验、ChIP-seq、RNA-seq整合分析及CRISPR/Cas9基因编辑等技术。
- 患者样本用于评估候选预后生物标志物。
主要发现
- THZ1是CDK7共价抑制剂,经高通量筛选鉴定为强效抗ATC化合物。
- ATC细胞而非甲状腺乳头状癌细胞对CDK7抑制异常敏感。
- 整合基因表达谱和SE特征分析发现SE介导的致癌转录扩增介导ATC细胞对THZ1的脆弱性。
- 发现新癌基因PPP1R15A、SMG9和KLF2,用Guanabenz或Sephin1抑制PPP1R15A可显著抑制ATC生长。
- PPP1R15A表达与CDK7表达在ATC组织样本中相关,两者高表达均与不良临床预后相关。
临床怎么用
- CDK7和PPP1R15A可作为ATC预后生物标志物和潜在治疗靶点。
- CDK7或PPP1R15A抑制联合常规化疗可能提高ATC治疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive malignancies, with no effective treatment currently available. The molecular mechanisms of ATC carcinogenesis remain poorly understood. The objective of this study was to investigate the mechanisms and functions of super-enhancer (SE)-driven oncogenic transcriptional addiction in the progression of ATC and identify new drug targets for ATC treatments. Methods: High-throughput chemical screening was performed to identify new drugs inhibiting ATC cell growth. Cell viability assay, colony formation analysis, cell-cycle analysis, and animal study were used to examine the effects of drug treatments on ATC progression. Chromatin immunoprecipitation sequencing was conducted to establish a SE landscape of ATC. Integrative analysis of RNA sequencing, chromatin immunoprecipitation sequencing, and CRISPR/Cas9-mediated gene editing was used to identify THZ1 target genes. Drug combination analysis was performed to assess drug synergy. Patient samples were analyzed to evaluate candidate biomarkers of prognosis in ATC. Results: THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), was identified as a potent anti-ATC compound by high-throughput chemical screening. ATC cells, but not papillary thyroid carcinoma cells, are exceptionally sensitive to CDK7 inhibition. An integrative analysis of both gene expression profiles and SE features revealed that the SE-mediated oncogenic transcriptional amplification mediates the vulnerability of ATC cells to THZ1 treatment. Combining this integrative analysis with functional assays led to the discovery of a number of novel cancer genes of ATC, including PPP1R15A, SMG9, and KLF2. Inhibition of PPP1R15A with Guanabenz or Sephin1 greatly suppresses ATC growth. Significantly, the expression level of PPP1R15A is correlated with CDK7 expression in ATC tissue samples. Elevated expression of PPP1R15A and CDK7 are both associated with poor clinical prognosis in ATC patients. Importantly, CDK7 or PPP1R15A inhibition sensitizes ATC cells to conventional chemotherapy. Conclusions: Taken together, these findings demonstrate transcriptional addiction in ATC pathobiology and identify CDK7 and PPP1R15A as potential biomarkers and therapeutic targets for ATC.
引用
- Cao X, Dang L, Zheng X, et al. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma. Thyroid. 2019. PMID: 30924726. doi:10.1089/thy.2018.0550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。